Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
February 10, 2010 Oramed Pharmaceuticals Inc. Israel
JERUSALEM, Israel, February 10 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer
of alternative drug delivery systems, announced today that its Chief
Scientific Officer, Miriam Kidron, Ph.D., was chosen to lecture at the Third
International Conference on Advanced Technologies and Treatments for Diabetes
(ATTD) to take place in Basel, Switzerland on February 11, 2010. Dr. Kidron
will present the following abstract in Hall B at 3:15 pm: "Assessment of Oral
Insulin Formulations in the Healthy Male Volunteers - Safety and
Pharmacodynamic Comparisons".
Based on the conference website, the conference "presents professionals
with cutting-edge technologies from entrepreneurs racing to develop effective
and advanced devices and systems for the treatment and prevention of diabetes
and related illnesses." For more information please visit the conference
website at: http://www2.kenes.com/attd/pages/home.aspx.
Oramed is currently conducting a Phase 2B clinical trial in South Africa
on its flagship product an oral insulin capsule. Results are expected at the
end of the first quarter of 2010.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at Jerusalem's Hadassah
Medical Center. Oramed's corporate and R&D headquarters are based in
Jerusalem.
For more information, please visit http://www.oramed.com.
Forward-looking statements
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Oramed, or industry results, to be materially
different from any future results, performance or achievements expressed or
implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and Oramed's ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to Oramed's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of Oramed to
differ materially from those expressed or implied in such forward looking
statements. Oramed undertakes no obligation to update or revise any
forward-looking statements.
